Skip to main content
. 2021 Feb 9;12(3):801–811. doi: 10.1007/s13300-021-01015-z

Fig. 1.

Fig. 1

Diabetes therapies used by patients prior to the initiation of semaglutide. DDP-IVi Dipeptidyl peptidase IV inhibitor, GLP-1RA glucagon-like peptide-1 receptor analogue, Met metformin, SGLT2i sodium-glucose co-transporter-2 inhibitor, SU sulfonylureas, TZD thiazolidinediones